TCGA-34-5241-01A-01R-1443-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 79
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.520
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.470
- INTERFERON_ALPHA_RESPONSE+0.410
- ALLOGRAFT_REJECTION+0.390
- MYC_TARGETS_V1+0.390
- INTERFERON_GAMMA_RESPONSE+0.380
- FATTY_ACID_METABOLISM+0.370
- INFLAMMATORY_RESPONSE+0.370
- HYPOXIA+0.360
- MTORC1_SIGNALING+0.360
Top 10 suppressed
- MITOTIC_SPINDLE-0.320
- HEDGEHOG_SIGNALING-0.250
- WNT_BETA_CATENIN_SIGNALING-0.240
- NOTCH_SIGNALING-0.200
- G2M_CHECKPOINT-0.150
- ESTROGEN_RESPONSE_EARLY-0.130
- MYC_TARGETS_V2-0.120
- UV_RESPONSE_DN-0.040
- PANCREAS_BETA_CELLS-0.020
- KRAS_SIGNALING_DN+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 551ADCCD-D116-43D8-AABC-E7E111D79E70 | — | — | 0.907 |
| 2 | AUR-AFUI-TTM1-A-1-0-R-A743-41 | — | C | 0.895 |
| 3 | 53D8CF8D-31BA-4CB8-A14F-5C9AB9554F5D | — | — | 0.895 |
| 4 | FBB4DAFD-11F1-498F-95C5-73D8B735465B | — | — | 0.880 |
| 5 | 70203945-80F8-4FA7-8C99-FEBAD3374103 | — | — | 0.869 |
| 6 | BDBF3ACE-7DC0-47C1-9B03-E2EDCF0B6CE6 | — | — | 0.868 |
| 7 | C3L-00913 | — | cohortA4 | 0.864 |
| 8 | 0E9EAAED-A9A2-41E7-AC3A-49E94C933432 | — | — | 0.861 |
| 9 | TCGA-38-4632-01A-01R-1755-07 | — | cohortA1 | 0.861 |
| 10 | 647EE729-B34A-41F0-85AB-207F8C24420B | — | — | 0.859 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.520 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.470 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.410 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.390 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.390 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.380 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.370 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| HYPOXIA | 0.360 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.340 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.330 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.320 | Remibrutinib | — uncovered |
| COAGULATION | 0.320 | Binimetinib | — uncovered |
| COMPLEMENT | 0.310 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| APOPTOSIS | 0.290 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.290 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.280 | Inavolisib | — uncovered |
| PEROXISOME | 0.280 | Idelalisib | — uncovered |